High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 47, Issue 9, Pages 1288-1295
Publisher
Wiley
Online
2018-03-15
DOI
10.1111/apt.14592
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug interactions in HIV-infected patients treated for hepatitis C
- (2017) Vicente Soriano et al. Expert Opinion on Drug Metabolism & Toxicology
- Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen
- (2017) Edward J. Gane et al. HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)
- (2017) Malte H. Wehmeyer et al. JOURNAL OF MEDICAL VIROLOGY
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
- (2017) Marc Bourlière et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
- (2017) Christoph Boesecke et al. Open Forum Infectious Diseases
- Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
- (2016) Eric J. Lawitz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study
- (2016) Jordan J. Feld et al. CLINICAL INFECTIOUS DISEASES
- Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)
- (2016) Patrick Ingiliz et al. CLINICAL INFECTIOUS DISEASES
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
- (2015) HEPATOLOGY
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
- (2015) Michael P. Curry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
- (2015) Julia Dietz et al. PLoS One
- Is genotype 3 of the hepatitis C virus the new villain?
- (2013) Nicolas Goossens et al. HEPATOLOGY
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
- (2013) Dennis Hernandez et al. JOURNAL OF CLINICAL VIROLOGY
- Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis
- (2011) A. Probst et al. JOURNAL OF VIRAL HEPATITIS
- Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
- (2008) A. ANDRIULLI et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now